Jon Sakoda - Net Worth and Insider Trading

Jon Sakoda Net Worth

The estimated net worth of Jon Sakoda is at least $58 Million dollars as of 2024-11-05. Jon Sakoda is the 10% Owner of Ardelyx Inc and owns about 5,331,039 shares of Ardelyx Inc (ARDX) stock worth over $31 Million. Jon Sakoda is the 10% Owner of AVEO Pharmaceuticals Inc and owns about 1,778,372 shares of AVEO Pharmaceuticals Inc (AVEO) stock worth over $27 Million. Jon Sakoda is also the 10% Owner of Achaogen Inc and owns about 5,215,128 shares of Achaogen Inc (AKAOQ) stock worth over $130,378. Besides these, Jon Sakoda also holds ARCA biopharma Inc (ABIO) . Details can be seen in Jon Sakoda's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jon Sakoda has not made any transactions after 2018-06-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jon Sakoda

Jon Sakoda Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jon Sakoda owns 10 companies in total, including AVEO Pharmaceuticals Inc (AVEO) , Ardelyx Inc (ARDX) , and Cascadian Therapeutics Inc (CASC) among others .

Click here to see the complete history of Jon Sakoda’s form 4 insider trades.

Insider Ownership Summary of Jon Sakoda

Ticker	Comapny	Transaction Date	Type of Owner
AVEO	AVEO Pharmaceuticals Inc	2018-06-28	10 percent owner
ARDX	Ardelyx Inc	2016-07-18	10 percent owner
CASC	Cascadian Therapeutics Inc	2018-03-09	10 percent owner
		2018-02-26	10 percent owner
		2018-01-19	10 percent owner
		2017-11-20	10 percent owner
		2017-07-24	10 percent owner
		2016-12-19	10 percent owner
		2015-05-27	director
		2018-01-19	10 percent owner

Jon Sakoda Latest Holdings Summary

Jon Sakoda currently owns a total of 4 stocks. Among these stocks, Jon Sakoda owns 5,331,039 shares of Ardelyx Inc (ARDX) as of July 18, 2016, with a value of $31 Million and a weighting of 53.48%. Jon Sakoda owns 1,778,372 shares of AVEO Pharmaceuticals Inc (AVEO) as of June 28, 2018, with a value of $27 Million and a weighting of 46.3%. Jon Sakoda also owns 5,215,128 shares of Achaogen Inc (AKAOQ) as of December 19, 2016, with a value of $130,378 and a weighting of 0.23%. The other 1 stocks ARCA biopharma Inc (ABIO) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Jon Sakoda

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ARDX	Ardelyx Inc	2016-07-18	5,331,039	5.78	30,813,405
AVEO	AVEO Pharmaceuticals Inc	2018-06-28	1,778,372	15.00	26,675,580
AKAOQ	Achaogen Inc	2016-12-19	5,215,128	0.03	130,378
ABIO	ARCA biopharma Inc	2018-02-26	0	25.50	0

Holding Weightings of Jon Sakoda

Jon Sakoda Form 4 Trading Tracker

According to the SEC Form 4 filings, Jon Sakoda has made a total of 0 transactions in Ardelyx Inc (ARDX) over the past 5 years. The most-recent trade in Ardelyx Inc is the acquisition of 1,527,301 shares on July 18, 2016, which cost Jon Sakoda around $13 Million.

According to the SEC Form 4 filings, Jon Sakoda has made a total of 0 transactions in AVEO Pharmaceuticals Inc (AVEO) over the past 5 years. The most-recent trade in AVEO Pharmaceuticals Inc is the acquisition of 19,243 shares on June 28, 2018, which cost Jon Sakoda around $404,092.

According to the SEC Form 4 filings, Jon Sakoda has made a total of 0 transactions in Achaogen Inc (AKAOQ) over the past 5 years. The most-recent trade in Achaogen Inc is the acquisition of 500,000 shares on December 19, 2016, which cost Jon Sakoda around $7 Million.

More details on Jon Sakoda's insider transactions can be found in the Insider Trading History of Jon Sakoda table.

Insider Trading History of Jon Sakoda

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jon Sakoda Trading Performance

GuruFocus tracks the stock performance after each of Jon Sakoda's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jon Sakoda is 55.22%. GuruFocus also compares Jon Sakoda's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jon Sakoda within 3 months outperforms 7 times out of 9 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jon Sakoda's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jon Sakoda

Average Return

Average return per transaction

Outperforming Transactions

2 out of 9 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	7.53
Relative Return to S&P 500(%)	6.08

Jon Sakoda Ownership Network

Ownership Network List of Jon Sakoda

No Data

Ownership Network Relation of Jon Sakoda

Jon Sakoda Owned Company Details

What does AVEO Pharmaceuticals Inc do?

Who are the key executives at AVEO Pharmaceuticals Inc?

Jon Sakoda is the 10 percent owner of AVEO Pharmaceuticals Inc. Other key executives at AVEO Pharmaceuticals Inc include Chief Operating Officer Jebediah Ledell , director & President & CEO Michael P Bailey , and Chief Commercial Officer Michael Ferraresso .

AVEO Pharmaceuticals Inc (AVEO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AVEO Pharmaceuticals Inc (AVEO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AVEO Pharmaceuticals Inc (AVEO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AVEO Pharmaceuticals Inc (AVEO)'s detailed insider trading history can be found in Insider Trading Tracker table.

AVEO Pharmaceuticals Inc Insider Transactions

No Available Data

What does Ardelyx Inc do?

Who are the key executives at Ardelyx Inc?

Jon Sakoda is the 10 percent owner of Ardelyx Inc. Other key executives at Ardelyx Inc include director & President & CEO Michael Raab , Chief Development Officer David P. Rosenbaum , and Chief Medical Officer Laura A Williams .

Ardelyx Inc (ARDX) Insider Trades Summary

Over the past 18 months, Jon Sakoda made no insider transaction in Ardelyx Inc (ARDX). Other recent insider transactions involving Ardelyx Inc (ARDX) include a net sale of 324,327 shares made by Michael Raab , a net sale of 247,172 shares made by David P. Rosenbaum , and a net sale of 490,778 shares made by Elizabeth A Grammer .

In summary, during the past 3 months, insiders sold 242,382 shares of Ardelyx Inc (ARDX) in total and bought 0 shares, with a net sale of 242,382 shares. During the past 18 months, 1,914,426 shares of Ardelyx Inc (ARDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,914,426 shares.

Ardelyx Inc (ARDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ardelyx Inc Insider Transactions

No Available Data

What does Cascadian Therapeutics Inc do?

Who are the key executives at Cascadian Therapeutics Inc?

Jon Sakoda is the 10 percent owner of Cascadian Therapeutics Inc. Other key executives at Cascadian Therapeutics Inc include 10 percent owner Nea 15 Gp, Llc , 10 percent owner Florence Anthony A. Jr. , and 10 percent owner Peter W. Sonsini .

Cascadian Therapeutics Inc (CASC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cascadian Therapeutics Inc (CASC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cascadian Therapeutics Inc (CASC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cascadian Therapeutics Inc (CASC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cascadian Therapeutics Inc Insider Transactions

No Available Data

What does ARCA biopharma Inc do?

Who are the key executives at ARCA biopharma Inc?

Jon Sakoda is the 10 percent owner of ARCA biopharma Inc. Other key executives at ARCA biopharma Inc include 10 percent owner & other: See Footnote 1 Funicular Funds, Lp , other: See Footnote 1 Funicular Fund, Lp , and other: See Remarks Jacob Ma-weaver .

ARCA biopharma Inc (ABIO) Insider Trades Summary

Over the past 18 months, Jon Sakoda made no insider transaction in ARCA biopharma Inc (ABIO). Other recent insider transactions involving ARCA biopharma Inc (ABIO) include a net purchase of 634,678 shares made by ,

In summary, during the past 3 months, insiders sold 0 shares of ARCA biopharma Inc (ABIO) in total and bought 485 shares, with a net purchase of 485 shares. During the past 18 months, 0 shares of ARCA biopharma Inc (ABIO) were sold and 52,890 shares were bought by its insiders, resulting in a net purchase of 52,890 shares.

ARCA biopharma Inc (ABIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARCA biopharma Inc Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

Jon Sakoda is the 10 percent owner of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , director & President and CEO William D Clark , and CHIEF FINANCIAL OFFICER Diantha Duvall .

Genocea Biosciences Inc (GNCAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GNCAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GNCAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GNCAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

What does X4 Pharmaceuticals Inc do?

Who are the key executives at X4 Pharmaceuticals Inc?

Jon Sakoda is the 10 percent owner of X4 Pharmaceuticals Inc. Other key executives at X4 Pharmaceuticals Inc include director & President and CEO Paula Ragan , Chief Scientific Officer Arthur Taveras , and Chief Operating Officer Mary Dibiase .

X4 Pharmaceuticals Inc (XFOR) Insider Trades Summary

Over the past 18 months, Jon Sakoda made no insider transaction in X4 Pharmaceuticals Inc (XFOR). Other recent insider transactions involving X4 Pharmaceuticals Inc (XFOR) include a net sale of 601,883 shares made by Paula Ragan , a net sale of 161,480 shares made by Mary Dibiase , and a net sale of 552,345 shares made by Adam S. Mostafa .

In summary, during the past 3 months, insiders sold 660,362 shares of X4 Pharmaceuticals Inc (XFOR) in total and bought 0 shares, with a net sale of 660,362 shares. During the past 18 months, 1,626,785 shares of X4 Pharmaceuticals Inc (XFOR) were sold and 25,000 shares were bought by its insiders, resulting in a net sale of 1,601,785 shares.

X4 Pharmaceuticals Inc (XFOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

X4 Pharmaceuticals Inc Insider Transactions

No Available Data

What does Regulus Therapeutics Inc do?

Who are the key executives at Regulus Therapeutics Inc?

Jon Sakoda is the 10 percent owner of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Sr. VP & General Counsel Christopher Ray Aker , Chief Operating Officer Joseph P Hagan , and Chief Financial Officer Crispina Calsada .

Regulus Therapeutics Inc (RGLS) Insider Trades Summary

Over the past 18 months, Jon Sakoda made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Crispina Calsada , and a net sale of 5,468 shares made by Christopher Ray Aker .

In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 21,516 shares.

Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Regulus Therapeutics Inc Insider Transactions

No Available Data

What does Achaogen Inc do?

Who are the key executives at Achaogen Inc?

Jon Sakoda is the 10 percent owner of Achaogen Inc. Other key executives at Achaogen Inc include 10 percent owner Robert W Duggan , Chief Operating Officer Elizabeth Bhatt , and See Remarks Gary Loeb .

Achaogen Inc (AKAOQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achaogen Inc (AKAOQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achaogen Inc (AKAOQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achaogen Inc (AKAOQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achaogen Inc Insider Transactions

No Available Data

What does Opower Inc do?

Who are the key executives at Opower Inc?

Jon Sakoda is the director of Opower Inc. Other key executives at Opower Inc include 10 percent owner Krishna Kittu Kolluri , 10 percent owner Scott D Sandell , and 10 percent owner M James Barrett .

Opower Inc (OPWR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Opower Inc (OPWR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Opower Inc (OPWR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Opower Inc (OPWR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Opower Inc Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

Jon Sakoda is the 10 percent owner of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , EVP PHARM SCI & MFG Stapleton Raymond D Jr , and 10 percent owner Paul Edward Walker .

Genocea Biosciences Inc (GGNNQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GGNNQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GGNNQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GGNNQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

Jon Sakoda Mailing Address

Above is the net worth, insider trading, and ownership report for Jon Sakoda. You might contact Jon Sakoda via mailing address: 2855 Sand Hill Road, Menlo Park Ca 94025.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.